Cargando...
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibrosis, patients were given 15 mg ruxolitinib orally...
Guardado en:
| Publicado en: | Haematologica |
|---|---|
| Autores principales: | , , , , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Ferrata Storti Foundation
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5004422/ https://ncbi.nlm.nih.gov/pubmed/26088933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.126821 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|